En­do los­es Va­sostrict patent bat­tle as sales take a hit from gener­ics

It’s been just two days since En­do In­ter­na­tion­al filed for bank­rupt­cy in an at­tempt to dig it­self out of thou­sands of opi­oid law­suits. Now one of its top sell­ers is in trou­ble.

A fed­er­al ap­peals court on Thurs­day af­firmed a Delaware judge’s de­ci­sion that Ea­gle Phar­ma­ceu­ti­cals’ gener­ic ver­sion of En­do’s va­so­pressin in­jec­tion Va­sostrict does not in­fringe on the com­pa­ny’s patents. Ea­gle’s ver­sion won ap­proval back in De­cem­ber, and al­ready, the gener­ic and oth­ers like it have dri­ven down Va­sostrict sales.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER